Emerging BioTalk
  • Home
  • About Us
  • Contact
  • Search
  • Menu
business meeting

The Post-COVID-19 State of Biomanufacturing News from the Biotech Start-up Symposium

January 18, 2022/in Bioprocessing, News /by Jessica Hogan

During last month’s Biotech Start-up Symposium, attendees heard an all-star team of experts discuss the intricacies of raising venture capital and a variety of other relevant topics. But no matter the discussion a single topic kept emerging–COVID-19.

Of all the industries affected by the pandemic, perhaps none was impacted more than biotech and pharma. During the symposium it became clear that some good news has actually come out of the pandemic. Inefficiencies within the industry were finally exposed and repaired, so the next time a new virus comes along we will be better prepared to tackle it.

According to Thomas Ransohoff of  Resilience, “The pandemic revealed two fundamental needs; first, that the resilience of domestic supply chains is crucial to health and economic security and secondly, that our ability to produce the complex medicines of the future at full scale is critical to our ability to deliver the benefits of these medicines.”

The manufacturing and deployment of the Pfizer and Moderna vaccines vindicated the second of Mr. Ransohoff’s points, as exemplified by two messenger RNA vaccines developed in record time despite not having been cleared for use in humans before. As of this writing over 8 billion doses have been administered worldwide and nearly 60% of the world population has received at least one dose1. A testament to our ingenuity and scalability.

During the symposium, Mr. Ransohoff also shared his thoughts on innovation in biomanufacturing. He says the introduction of new technologies is possible but still challenging, highlighting the need for companies such as Resilience who are focused on this capability. Additionally, the benefits of any new innovations need to be consistent with the level of effort put into getting them to market.

Simon Agwale of Innovative Biotech, Nigeria also shared his experience with COVID-19 vaccine development and manufacturing in Africa. After their previous contract development and manufacturing company (CDMO) was unable to meet timelines,

MilliporeSigma
Merck
EB connected Mr. Agwale and Innovative Biotech with 2019 EB Grant Winner – Technovax. Mr. Agwale described how they are now focused on developing a virus-like particle (VLP) vaccine for COVID-19 and currently have one for the Beta and Delta variants. Trials begin in Ghana, Nigeria and South Africa soon and will finish in the third quarter of 2022. Production of the new vaccine will be done in the United States until the new factory in Nigeria is constructed with full production to follow in Africa some time in 2023.

Given all the attention the biotech sector has had over the past two years, more innovations and news are sure to follow in 2022 and beyond.

  1. Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations. Accessed December 7, 2021.
  • Author
  • Recent Posts
Simon Agwale
Simon Agwale, Ph. D is the CEO of Innovative Biotech, Nigeria and Innovative Biotech USA Inc. He is a member of the board of the African Vaccine Manufacturers’ Initiative (AVMI) and in 2019 was asked to lead their Covid-19 Vaccine Task Team. He is also an advisor to WAHO, and part of a recently established ECOWAS vaccines taskforce. He is currently the Lead (Technology and IP) of Partnership for Africa Vaccines Manufacturing (PAVM) of Africa Centers for Disease Control (AfricaCDC).
Dr. Agwale has a vision for the development and investigation of HIV vaccine constructs from prevalent Nigerian strains which are relevant to Nigerians. He is also currently developing novel vaccines against Covid-19, Ebola, cervical cancer, and HIV using innovative viral-like particles (VLPs). Through INNOVATIVE, Dr. Agwale is striving to further develop and refine these dynamic, novel treatments, and in doing so, expand domestic vaccine manufacturing capabilities in Nigeria to serve the African community.
Dr. Agwale was a Postdoc fellow at the Institute of Human Virology Baltimore, USA and Visiting Scientist at various institutions in Brazil, Germany, UK including the US Vaccine Research Center/NIH, and US Center for Disease Control and prevention in Atlanta. Dr. Agwale was West Africa’s representative on HIV/AIDS for Developing countries Coordinating Committee (DCCC) at European and Developing Countries Clinical Trials Programme, where he was also the chair of the African Scientists committee (DCCC). He is a recipient of several scholarships, fellowships and grants from reputable organizations around the world. He has also authored and co-authored numerous noteworthy publications.
Latest posts by Simon Agwale (see all)
    • Author
    • Recent Posts
    Thomas Ransohoff
    M.S. Technical Head, Biologicals Franchise at National Resilience, Inc. at Resilience, Inc.
    Thomas C. Ransohoff, M.S is currently Technical Head, Biologicals Franchise at National Resilience, Inc. (“Resilience”) and has over 30 years of experience in the biopharmaceutical industry. Mr. Ransohoff’s areas of expertise include development and scale-up of biopharmaceutical processes; separations and purification technologies; cGMP manufacturing; and management of technology-based start-up ventures. Before joining Resilience, Mr. Ransohoff was a Managing Director at BDO and its precursor BPTC, a leading CMC consulting firm that he helped build over a 20 year period. Prior to that, he held senior level positions at TranXenoGen, Dyax, Repligen, and Xoma. He is also a co-founder of several successful start-ups, including 4th Dimension Bioprocess, Tarpon Biosystems and BioFlash Partners. He serves on a number of scientific and professional advisory boards and holds a Bachelor’s degree from MIT and a Master’s degree from the University of California, Berkeley, both in Chemical Engineering.
    Latest posts by Thomas Ransohoff (see all)

       

       

       

      +1
      Share this entry
      • Share on Facebook
      • Share on Twitter
      • Share on LinkedIn
      • Share by Mail
      http://emergingbiotalk.com/wp-content/uploads/2021/05/GettyImages-867416914-scaled.jpg 1707 2560 Jessica Hogan http://emergingbiotalk.com/wp-content/uploads/2020/05/emergingbiotalk-header.png Jessica Hogan2022-01-18 12:26:482022-10-19 08:53:05The Post-COVID-19 State of Biomanufacturing News from the Biotech Start-up Symposium

      Biotech Resource Hub >>

      • SUBSCRIBE TO OUR BLOG
      • SUBMIT YOUR BLOG POST

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar

      Archives

      • February 2023
      • January 2023
      • December 2022
      • November 2022
      • October 2022
      • September 2022
      • August 2022
      • July 2022
      • May 2022
      • April 2022
      • March 2022
      • February 2022
      • January 2022
      • November 2021
      • October 2021
      • September 2021
      • August 2021
      • July 2021
      • June 2021
      • May 2021
      • April 2021
      • March 2021
      • February 2021
      • January 2021
      • December 2020
      • November 2020
      • October 2020
      • September 2020
      • August 2020
      • July 2020
      • May 2020
      • April 2020
      • SUBSCRIBE TO OUR BLOG
      • SUBMIT YOUR BLOG POST

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar

      Archives

      • February 2023
      • January 2023
      • December 2022
      • November 2022
      • October 2022
      • September 2022
      • August 2022
      • July 2022
      • May 2022
      • April 2022
      • March 2022
      • February 2022
      • January 2022
      • November 2021
      • October 2021
      • September 2021
      • August 2021
      • July 2021
      • June 2021
      • May 2021
      • April 2021
      • March 2021
      • February 2021
      • January 2021
      • December 2020
      • November 2020
      • October 2020
      • September 2020
      • August 2020
      • July 2020
      • May 2020
      • April 2020

      Tags

      applications bioprocessing biotech blazar Congratulations Content education Europe FDA Format gene therapy grant grants Investigator's Brochure molecule new NGS Pharmaceuticals program services symposia tags things Tone VAR2 viral assurance viral clearance virus virus detection winner

      Business Hours

      Our support Hotline is available 24 Hours a day: (555) 343 456 7891

      • Monday-Friday: 9am to 5pm
      • Saturday: 10am to 2pm
      • Sunday: Closed

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am
      • The Future of BiopharmaDecember 6, 2022 - 4:39 am
      • Last chance: 3rd Annual Startup Symposium – Day 3November 10, 2022 - 5:39 am
      • The Lack of Funding for Women Entrepreneurs Doesn’t Stop Them from Launching – But We Still Have a Long Way to Go – And We Can Help Each Other. Assurea is ROOTING FOR YOU!October 21, 2022 - 8:27 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar
      • Author
      • Recent Posts
      Thomas Ransohoff
      M.S. Technical Head, Biologicals Franchise at National Resilience, Inc. at Resilience, Inc.
      Thomas C. Ransohoff, M.S is currently Technical Head, Biologicals Franchise at National Resilience, Inc. (“Resilience”) and has over 30 years of experience in the biopharmaceutical industry. Mr. Ransohoff’s areas of expertise include development and scale-up of biopharmaceutical processes; separations and purification technologies; cGMP manufacturing; and management of technology-based start-up ventures. Before joining Resilience, Mr. Ransohoff was a Managing Director at BDO and its precursor BPTC, a leading CMC consulting firm that he helped build over a 20 year period. Prior to that, he held senior level positions at TranXenoGen, Dyax, Repligen, and Xoma. He is also a co-founder of several successful start-ups, including 4th Dimension Bioprocess, Tarpon Biosystems and BioFlash Partners. He serves on a number of scientific and professional advisory boards and holds a Bachelor’s degree from MIT and a Master’s degree from the University of California, Berkeley, both in Chemical Engineering.
      Latest posts by Thomas Ransohoff (see all)
        +1
        © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. | Privacy Policy | Cookie Settings
        Another Successful Biotech Start-Up Symposium Is In The Books Biotech Hubs, Incubators and Clusters: Why You Need More Than Just Lab Spac...
        Scroll to top

        This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to allow. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy

        Accept All CookiesCookie Settings

        Cookie and Privacy Settings



        Cookie Preferences

        When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about how we use and share your data, please follow this link.
        Privacy Statement

        Necessary

        Always Active
        These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

        Functional

        These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).Changes will take effect once you reload the page.

        Targeting

        These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.

        Confirm My ChoicesAllow AllDisable All

        loading

        Please wait while you are redirected to the right page...

        Please share your location to continue.

        Check our help guide for more info.

        share your location